{"product_id":"alxo-vrio-analysis","title":"ALX Oncology Holdings Inc. (ALXO): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secret to ALX Oncology Holdings Inc. (ALXO)'s market staying power! This VRIO analysis rigorously tests its core assets against the pillars of Value, Rarity, Inimitability, and Organization to reveal if its current success is truly sustainable. Don't just guess its future - read the distilled findings below to see the definitive verdict on its competitive edge.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eALX Oncology Holdings Inc. (ALXO) - VRIO Analysis: Evorpacept: Best-in-Class CD47 Blocker Candidate\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at ALX Oncology Holdings Inc. (ALXO) to see if their lead asset, evorpacept, is truly a game-changer in the crowded immuno-oncology space. Honestly, the Q3 2025 numbers show they are still in heavy investment mode, reporting a GAAP net loss of \u003cstrong\u003e$22.1 million\u003c\/strong\u003e, but the clinical data is what matters most for long-term value.\u003c\/p\u003e\n\n\u003ch\u003eEvorpacept: Best-in-Class CD47 Blocker Candidate\u003c\/h\u003e\n\n\u003ch\u003eValue: Evorpacept, the lead therapeutic, is a potential best-in-class CD47 checkpoint inhibitor designed to activate the innate immune system, offering a novel approach to cancer treatment.\u003c\/h\u003e\n\u003cp\u003eEvorpacept is designed to block the CD47 \"don't eat me\" signal, which cancer cells use to hide from macrophages. The value proposition is crystal clear: when it works, it works exceptionally well, especially when you select patients based on CD47 expression. The data from the ASPEN-06 trial in HER2-positive gastric cancer patients with high CD47 expression is compelling. Here’s the quick math on the benefit:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eEvorpacept + TRP Arm\u003c\/th\u003e\n\u003cth\u003eControl (TRP) Arm\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eObjective Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e65.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Duration of Response (DOR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25.5 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.4 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Progression-Free Survival (PFS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18.4 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.0 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Overall Survival (OS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17.0 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~9.9 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides is that the combination achieved a PFS hazard ratio of \u003cstrong\u003e0.39\u003c\/strong\u003e against the control, meaning a massive reduction in the risk of disease progression. That’s real patient value, but only for the right patient subset.\u003c\/p\u003e\n\n\u003ch\u003eRarity: While other CD47 blockers exist, evorpacept's novel design and advanced clinical stage position it as a relatively rare, highly differentiated asset in the immuno-oncology space.\u003c\/h\u003e\n\u003cp\u003eThe CD47 space is getting crowded, with more than 20 distinct molecules in clinical development, but not all are created equal. A key differentiator for ALX Oncology is managing the hematologic side effects, like severe anemia, which plague other CD47 antibodies due to binding to red blood cells. Evorpacept’s design, which aims for reduced binding to red blood cells, makes it a rarer, potentially safer profile compared to some first-generation assets. Still, demonstrating this safety advantage consistently across indications is crucial.\u003c\/p\u003e\n\n\u003ch\u003eImitability: Imitating the exact molecule and its specific clinical profile, especially with positive data in combination therapies, is difficult and time-consuming for competitors.\u003c\/h\u003e\n\u003cp\u003eYou can’t just copy the molecule; you have to replicate the entire clinical journey, which takes years and hundreds of millions of dollars. Competitors face the challenge of replicating the specific, positive outcomes seen in biomarker-selected populations, like the \u003cstrong\u003e65.0%\u003c\/strong\u003e ORR in CD47-high gastric patients. Plus, ALX Oncology is pivoting its strategy to focus on CD47 as a predictive biomarker, which is a strategic move that others might be slow to adopt or replicate effectively. It’s not just the drug; it’s the data package that builds the moat.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: The company is clearly organized around evorpacept, prioritizing its development across multiple indications, including the ongoing ASPEN-06 and upcoming ASPEN-09 trials.\u003c\/h\u003e\n\u003cp\u003eALX Oncology is putting all its chips on evorpacept, which simplifies focus but concentrates risk. Financially, they are managing the burn to support this focus; their cash balance of \u003cstrong\u003e$66.5 million\u003c\/strong\u003e as of September 30, 2025, gives them a runway extending into Q1 2027. This runway is specifically timed to cover key value-driving events, like the First Patient In (FPI) for the ASPEN-09-Breast Cancer trial in Q4 2025 and interim data from that trial in Q3 2026. They’ve also smartly stopped pursuing underperforming PD-1 combination paths (ASPEN-03\/04), showing disciplined resource allocation. If onboarding for ASPEN-09 takes 14+ days longer than planned, churn risk rises for that cash runway.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage: Sustained, provided clinical efficacy continues to outpace competitors targeting the same pathway.\u003c\/h\u003e\n\u003cp\u003eRight now, the advantage is \u003cstrong\u003etemporary\u003c\/strong\u003e, leaning toward sustained if the biomarker strategy holds. The magnitude of benefit in the CD47-high subset - a median OS of \u003cstrong\u003e17.0 months\u003c\/strong\u003e versus about \u003cstrong\u003e9.9 months\u003c\/strong\u003e for control - is a significant differentiator that, if replicated in breast cancer (ASPEN-09), could establish evorpacept as the preferred CD47 blocker. To make this sustained, ALX Oncology needs to secure regulatory approval or a major partnership before the cash runs out in Q1 2027. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eALX Oncology Holdings Inc. (ALXO) - VRIO Analysis: CD47 Biomarker-Driven Patient Selection Strategy\n\u003c\/h2\u003e\n\u003cp\u003eCD47 Biomarker-Driven Patient Selection Strategy\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eIdentifying CD47 overexpression as a key predictive biomarker in the ASPEN-06 trial allows for targeted patient selection, potentially boosting response rates and improving development efficiency. The objective response rate (ORR) for patients with high CD47 expression treated with evorpacept plus trastuzumab, ramucirumab, and paclitaxel (TRP) in the Phase 2 portion of ASPEN-06 was \u003cstrong\u003e65.0%\u003c\/strong\u003e (n=43), compared to \u003cstrong\u003e26.1%\u003c\/strong\u003e for TRP alone in that subgroup.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePatient Group (ASPEN-06)\u003c\/th\u003e\n\u003cth\u003eTreatment Arm\u003c\/th\u003e\n\u003cth\u003eObjective Response Rate (ORR)\u003c\/th\u003e\n\u003cth\u003eN\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHER2+ Gastric\/GEJ, CD47-High\u003c\/td\u003e\n\u003ctd\u003eEvorpacept + TRP\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e65.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e43\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHER2+ Gastric\/GEJ, CD47-High\u003c\/td\u003e\n\u003ctd\u003eTRP Only\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHER2+ Gastric\/GEJ, CD47-Low\u003c\/td\u003e\n\u003ctd\u003eEvorpacept + TRP\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e37.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e47\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHER2+ Gastric\/GEJ, CD47-Low\u003c\/td\u003e\n\u003ctd\u003eTRP Only\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe Phase 2 portion of the ASPEN-06 trial enrolled \u003cstrong\u003e127\u003c\/strong\u003e adult patients.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThis specific, validated biomarker-efficacy link for a CD47 blocker in indications like HER2-positive gastric cancer is rare and provides a clear development advantage. The demonstration of a \u003cstrong\u003e38.9 percentage point\u003c\/strong\u003e absolute difference in ORR (65.0% vs 26.1%) attributable to evorpacept in the CD47-high group suggests a strong, rare signal.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eCompetitors can try to find similar biomarkers, but replicating ALX Oncology’s specific data set and clinical proof-of-concept is challenging. The company's R\u0026amp;D expenses for the year ended December 31, 2024, were \u003cstrong\u003e$116.4 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe strategy is actively guiding development, such as amending the ASPEN-09 Breast Cancer trial to evaluate responses by CD47 expression level. The ASPEN-09 trial is on track for first patient in (FPI) in \u003cstrong\u003eQ4 2025\u003c\/strong\u003e, with an interim data readout anticipated in \u003cstrong\u003eQ3 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company's cash runway is expected to extend into \u003cstrong\u003eQ1 2027\u003c\/strong\u003e, supporting these key milestones.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (“R\u0026amp;D”) expenses for the three months ended December 31, 2024, were \u003cstrong\u003e$23.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary, as competitors will rapidly adopt similar biomarker strategies if the approach proves broadly successful. The GAAP net loss for the three months ended December 31, 2024, was \u003cstrong\u003e($29.2) million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eALX Oncology Holdings Inc. (ALXO) - VRIO Analysis: ALX2004: Differentiated Antibody-Drug Conjugate (ADC) Pipeline Asset\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e ALX2004, an EGFR-targeted ADC, diversifies the pipeline beyond CD47 inhibition, addressing solid tumors with a mechanism that showed potent preclinical anti-tumor activity.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Having a second, distinct, late-stage molecule entering the clinic in August 2025 provides pipeline depth uncommon for many clinical-stage biotechs.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The specific design of the ADC, including its linker-payload, is proprietary and harder to copy than a standard antibody, utilizing the Company's proprietary topoisomerase I inhibitor (Top1i) payload and linker payload platform.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is supporting its Phase 1 trial (NCT07085091), with initial safety data expected in the first half of 2026. The Q3 2025 net loss was $22.14 million, with cash runway expected into Q1 2027.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the success hinges on early clinical data which is not yet fully public.\u003c\/p\u003e\n\u003cp\u003eALX2004 Design and Trial Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eDetail\/Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Initiation (First Patient Dosed)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAugust 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Safety Data Expected\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eFirst Half of 2026\u003c\/strong\u003e (1H 2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Indication Start Cohorts\u003c\/td\u003e\n\u003ctd\u003eNSCLC, HNSCC, ESCC, and CRC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.14 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Investments (as of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$66.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Guidance\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eQ1 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eProprietary ADC Components:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAntibody Backbone: Matuzumab-derived EGFR antibody with a binding epitope distinct from FDA-approved EGFR antibodies.\u003c\/li\u003e\n\u003cli\u003ePayload: Proprietary topoisomerase I inhibitor (Top1i).\u003c\/li\u003e\n\u003cli\u003eLinker: Engineered for improved linker stability for on-target delivery.\u003c\/li\u003e\n\u003cli\u003ePreclinical Profile: Demonstrated superior stability versus other ADCs in its class.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eALX Oncology Holdings Inc. (ALXO) - VRIO Analysis: Proprietary Linker-Payload Technology for ALX2004\n\u003c\/h2\u003e\n\n\u003ch3\u003eProprietary Linker-Payload Technology for ALX2004\u003c\/h3\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This underlying technology is what enables the creation of ALX2004, potentially allowing for the development of future ADCs with differentiated mechanisms and favorable preclinical safety profiles.\u003c\/p\u003e\n\u003cp\u003ePreclinical data supported a differentiated safety profile:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNo evidence of payload-related Interstitial Lung Disease (ILD) in Non-human primate (NHP) toxicity studies.\u003c\/li\u003e\n\u003cli\u003eNo demonstration of EGFR-related skin toxicity at clinically relevant doses in preclinical model findings.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Proprietary ADC platforms are scarce; they represent a core technological capability beyond just one drug candidate. The technology was \u003cstrong\u003efully designed and developed in-house\u003c\/strong\u003e by ALX Oncology scientists.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; developing a novel, validated linker-payload system requires significant R\u0026amp;D investment and time.\u003c\/p\u003e\n\u003cp\u003eThe platform is the basis for ALX2004, which utilized proprietary Topoisomerase I inhibitor (Top1i) payload and linker technology.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The platform was used to create ALX2004, which entered the clinic, demonstrating the capability to translate platform science into clinical assets.\u003c\/p\u003e\n\u003cp\u003eKey progression milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInvestigational New Drug (IND) clearance received from the U.S. Food and Drug Administration (FDA) in April 2025.\u003c\/li\u003e\n\u003cli\u003ePhase 1 clinical trial enrollment began in August 2025.\u003c\/li\u003e\n\u003cli\u003eInitial safety data anticipated in the first half of 2026 (1H 2026).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as the platform itself is a source of future innovation and potential partnerships.\u003c\/p\u003e\n\u003cp\u003eFinancial context related to development investment and runway:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003eThree Months Ended September 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Investments\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$66.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Guidance\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003ctd\u003eInto Q1 of 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003ePreclinical comparison of the proprietary linker-payload construct:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAttribute\u003c\/td\u003e\n\u003ctd\u003eALX2004 Proprietary Construct\u003c\/td\u003e\n\u003ctd\u003eOther ADCs in Class (Contextual)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLinker Stability\u003c\/td\u003e\n\u003ctd\u003eDemonstrated \u003cstrong\u003esuperior stability\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eComparison point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayload\u003c\/td\u003e\n\u003ctd\u003eProprietary Topoisomerase I inhibitor (Top1i)\u003c\/td\u003e\n\u003ctd\u003ePast attempts limited by payload classes (e.g., MMAE toxicities)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBystander Effect\u003c\/td\u003e\n\u003ctd\u003eEngineered for \u003cstrong\u003eenhanced bystander effect\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntibody Epitope\u003c\/td\u003e\n\u003ctd\u003eBinding epitope \u003cstrong\u003edistinct from FDA-approved EGFR antibodies\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eALX Oncology Holdings Inc. (ALXO) - VRIO Analysis: Clinical Data Readout Momentum (SITC 2025)\n\u003c\/h2\u003e\n\u003cp\u003eThe momentum is centered on the presentation of updated data from the Phase 2 portion of the ASPEN-06 trial at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 5–9, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Presenting compelling data from the Phase 2 ASPEN-06 trial at the SITC Annual Meeting in November 2025 validates the core scientific hypothesis and drives investor\/partner interest.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe value proposition is supported by prior data demonstrating substantial benefit in the biomarker-enriched population:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eEvorpacept + Backbone (CD47-High)\u003c\/td\u003e\n\u003ctd\u003eControl Arm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConfirmed Objective Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e48.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e24.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Duration of Response (mDOR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15.7 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9.1 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgression-Free Survival (PFS) Hazard Ratio\u003c\/td\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003e0.64\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe Phase 2 portion of ASPEN-06 enrolled \u003cstrong\u003e127 adult patients\u003c\/strong\u003e with previously treated HER2-positive advanced gastric\/GEJ adenocarcinoma. The combination regimen included evorpacept plus HERCEPTIN, CYRAMZA, and paclitaxel.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: The specific data set showing a durable clinical benefit in CD47-high patients is unique to ALX Oncology’s trials at this moment.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEvorpacept is highlighted as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized trial.\u003c\/li\u003e\n\u003cli\u003eThe data specifically focus on CD47 overexpression as a predictive biomarker for evorpacept response.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: The data itself cannot be imitated, though competitors can generate their own data.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific clinical outcomes achieved in the ASPEN-06 trial (e.g., \u003cstrong\u003e48.9%\u003c\/strong\u003e ORR in the biomarker group) are historical facts and cannot be replicated by competitors; however, competitors can pursue similar mechanistic approaches.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: The executive team is clearly organized to present this data and leverage it for the next trial phase (ASPEN-09).\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFinancial and operational data as of September 30, 2025, indicate organizational capacity:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, and investments totaled \u003cstrong\u003e$66.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThis cash position is expected to fund operations into \u003cstrong\u003eQ1 2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company reported a GAAP net loss of \u003cstrong\u003e$22.1 million\u003c\/strong\u003e (or \u003cstrong\u003e$0.41 per share\u003c\/strong\u003e) for Q3 2025, with Research and Development (R\u0026amp;D) expenses at \u003cstrong\u003e$17.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe team is on track to leverage this data by beginning enrollment for the ASPEN-09-Breast Cancer trial in \u003cstrong\u003eQ4 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary, as data is time-sensitive and its impact fades as competitors present their own results.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is time-bound, dependent on being the first to validate the CD47 biomarker strategy in this setting, with interim data for the next planned trial (ASPEN-09) anticipated in \u003cstrong\u003eQ3 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eALX Oncology Holdings Inc. (ALXO) - VRIO Analysis: Seasoned Executive Team with Biotech M\u0026amp;A\/Scaling Experience\n\u003c\/h2\u003e\n\u003cp\u003eThe current executive and board composition reflects a strategic focus on navigating late-stage clinical development and potential commercialization or transaction events, evidenced by the recent high-profile appointments in \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSeasoned Executive Team with Biotech M\u0026amp;A\/Scaling Experience\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Leadership includes executives with experience guiding companies through late-stage development and significant M\u0026amp;A events, like the CFO’s prior work leading up to a $4.3 billion acquisition.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe value proposition is anchored by executive experience in successful high-value transactions and scaling operations:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eExecutive Role\u003c\/th\u003e\n\u003cth\u003eKey Experience Highlight\u003c\/th\u003e\n\u003cth\u003eTransaction\/Scaling Metric\u003c\/th\u003e\n\u003cth\u003eAppointment Date at ALXO\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCFO (Harish Shantharam)\u003c\/td\u003e\n\u003ctd\u003eGuided CymaBay Therapeutics through its acquisition by Gilead Sciences.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e acquisition. Over \u003cstrong\u003e20 years\u003c\/strong\u003e of finance\/commercial experience.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterim CMO (Dr. Barbara Klencke)\u003c\/td\u003e\n\u003ctd\u003eServed as CMO of Sierra Oncology through its acquisition.\u003c\/td\u003e\n\u003ctd\u003eSierra Oncology acquired by GlaxoSmithKline (GSK) in 2022; Dr. Klencke has over \u003cstrong\u003e30 years\u003c\/strong\u003e of experience.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeptember 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBoard Member (Dr. Chris Takimoto)\u003c\/td\u003e\n\u003ctd\u003ePreviously CMO of Forty Seven, Inc. until its acquisition by Gilead Sciences.\u003c\/td\u003e\n\u003ctd\u003eForty Seven acquired by Gilead Sciences for \u003cstrong\u003e$4.9 billion\u003c\/strong\u003e. Over \u003cstrong\u003e17 years\u003c\/strong\u003e of industry experience.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO (Jason Lettmann)\u003c\/td\u003e\n\u003ctd\u003eCo-led ALXO's first institutional financing. Prior company acquisition experience.\u003c\/td\u003e\n\u003ctd\u003ePrior company, Promedior, acquired by Roche in 2020 for up to \u003cstrong\u003e$1.39 billion\u003c\/strong\u003e.\u003c\/td\u003e\n\u003ctd\u003eCEO since \u003cstrong\u003eSeptember 2023\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: The blend of deep clinical oncology leadership (CMO) and finance\/scaling expertise (CFO) is valuable in the current market.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe rarity stems from the specific, recent combination of expertise:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical Oncology Depth:\u003c\/strong\u003e Dr. Klencke (Interim CMO) has over \u003cstrong\u003e30 years\u003c\/strong\u003e of experience, including leading a company through acquisition. Dr. Takimoto (Board) has experience from a \u003cstrong\u003e$4.9 billion\u003c\/strong\u003e acquisition.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial\/M\u0026amp;A Acumen:\u003c\/strong\u003e CFO Shantharam brings direct experience from a \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e transaction and previously supported a business segment with \u003cstrong\u003e$20 to $30 billion-dollar\u003c\/strong\u003e in revenue at Gilead Sciences.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: High; this specific combination of experience and internal relationships is not easily replicated by hiring a few new people.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe difficulty in imitation is due to the embedded knowledge of past successful transactions, which is not transferable through standard recruitment processes. The leadership team is focused on advancing evorpacept into late-stage clinical trials in 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Recent appointments in 2025 (CFO in Jan, CMO in Sept) show an organization focused on operational excellence for growth.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organizational structure has been actively refined in \u003cstrong\u003e2025\u003c\/strong\u003e to support the next corporate phase:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCFO Harish Shantharam appointed in \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDr. Barbara Klencke appointed Interim CMO in \u003cstrong\u003eSeptember 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's Market Capitalization as of recent data is \u003cstrong\u003e$87.03M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained, as strong leadership is a persistent factor in navigating clinical and financial hurdles.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe sustained advantage is derived from leadership proven to manage high-stakes transitions, such as the planned late-stage advancement of evorpacept. The current Average Trading Volume is reported as \u003cstrong\u003e1,027,616\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eALX Oncology Holdings Inc. (ALXO) - VRIO Analysis: Extended Cash Runway into Q1 2027\n\u003c\/h2\u003e\n\n\u003ch\u003eValue: Having $66.5 million in cash, cash equivalents, and investments as of September 30, 2025, with a runway extending into Q1 2027, reduces immediate financing risk.\u003c\/h\u003e\n\u003cp\u003eThe cash position of \u003cstrong\u003e$66.5 million\u003c\/strong\u003e as of September 30, 2025, provides operational funding until \u003cstrong\u003eQ1 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue as of Sep 30, 2025\u003c\/td\u003e\n\u003ctd\u003ePrior Period Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$66.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$83.5 million (Q2 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eQ1 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eInto Q4 2026 (Q1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Data Milestones Covered\u003c\/td\u003e\n\u003ctd\u003eALX2004 initial safety data (\u003cstrong\u003e1H 2026\u003c\/strong\u003e); ASPEN-09-Breast interim (\u003cstrong\u003eQ3 2026\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity: In the biotech sector, extending runway past the next 12 months to cover key data readouts (like ALX2004 safety in 1H 2026) is a significant, though not unique, advantage.\u003c\/h\u003e\n\u003cp\u003eThe runway covers critical value-inflection points, specifically the \u003cstrong\u003eALX2004\u003c\/strong\u003e initial safety data in \u003cstrong\u003e1H 2026\u003c\/strong\u003e and the \u003cstrong\u003eASPEN-09-Breast\u003c\/strong\u003e interim data in \u003cstrong\u003eQ3 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003eImitability: Low, as it is a result of past financing and current cost control, not an inherent asset.\u003c\/h\u003e\n\u003cp\u003eThe extended runway is a direct consequence of recent financial management actions, not a proprietary resource.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGAAP Net Loss for Q3 2025: \u003cstrong\u003e$22.1 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eGAAP Net Loss for Q3 2024: \u003cstrong\u003e$30.7 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) Expenses for Q3 2025: \u003cstrong\u003e$17.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eGeneral and Administrative (G\u0026amp;A) Expenses for Q3 2025: \u003cstrong\u003e$5.1 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eOrganization: The company demonstrated financial discipline by pausing the ASPEN-CRC trial to achieve this runway extension.\u003c\/h\u003e\n\u003cp\u003eThe strategic prioritization included pausing the \u003cstrong\u003eASPEN-CRC\u003c\/strong\u003e study in colorectal cancer.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage: Temporary, as the runway is a depleting resource that must be managed until the next financing event or commercial success.\u003c\/h\u003e\n\u003cp\u003eThe cash balance is a non-renewable asset that decreases with every operational quarter.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eALX Oncology Holdings Inc. (ALXO) - VRIO Analysis: Focused Clinical Development Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e By pausing the ASPEN-CRC trial in colorectal cancer and focusing resources on evorpacept in breast cancer (ASPEN-09) and ALX2004, the company concentrates capital on the highest-potential assets, extending the cash runway into \u003cstrong\u003eQ1 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e This level of strategic focus, driven by the identification of CD47 overexpression as a key predictive biomarker for evorpacept response from the ASPEN-06 gastric cancer trial, is a necessary but not always present discipline in R\u0026amp;D organizations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy for competitors to copy the action (pausing a trial), but hard to copy the insight that led to the decision, which was derived from exploratory analysis of the ASPEN-06 trial data showing differential response based on CD47 expression.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The Q3 2025 R\u0026amp;D expenses of \u003cstrong\u003e$17.4 million\u003c\/strong\u003e reflect this streamlined focus compared to the prior year's \u003cstrong\u003e$26.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the benefit is realized only until the next set of data requires a strategic pivot, with the next key readout being interim data from the ASPEN-09 Breast Cancer trial in \u003cstrong\u003eQ3 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe financial and operational shifts supporting this focus are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Target\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 R\u0026amp;D Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior Year R\u0026amp;D Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$66.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eQ1 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASPEN-09 Breast Cancer Enrollment Start\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ4 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTarget\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALX2004 Initial Safety Data\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFirst Half of 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTarget\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe strategic focus is underpinned by specific clinical data points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIn patients with retained HER2+ and CD47-high gastric cancer from ASPEN-06 ($n=43$), evorpacept + TRP had a \u003cstrong\u003e65.0%\u003c\/strong\u003e Objective Response Rate (ORR).\u003c\/li\u003e\n\u003cli\u003eIn the same patient population, the ORR for TRP alone was \u003cstrong\u003e26.1%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Phase 2 ASPEN-09-Breast Cancer trial is designed to evaluate evorpacept efficacy by CD47 expression levels.\u003c\/li\u003e\n\u003cli\u003eALX2004, a novel EGFR-targeted ADC, entered the clinic in a Phase 1 trial in August 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eALX Oncology Holdings Inc. (ALXO) - VRIO Analysis: Intellectual Property Coverage on Lead Assets\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eIntellectual Property Coverage on Lead Assets\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: Patents covering the composition of matter for key candidates, like the one for ALX148 extending coverage past \u003cstrong\u003e2036\u003c\/strong\u003e, provide a crucial moat against generic competition.\u003c\/p\u003e\n\u003cp\u003eRarity: Strong patent protection on the core mechanism (CD47 inhibition) and the novel ADC platform is essential and not guaranteed.\u003c\/p\u003e\n\u003cp\u003eImitability: Very high barrier; patent law makes direct imitation of the molecule's composition legally prohibitive.\u003c\/p\u003e\n\u003cp\u003eOrganization: The IP portfolio supports the ongoing and planned clinical trials, giving confidence to partners and investors.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Sustained, as long as the core patents remain in force.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\/Metric\u003c\/th\u003e\n\u003cth\u003ePatent\/Financial Data Point\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eALX148 Composition of Matter Patent Expiration (Excl. Adjustments)\u003c\/td\u003e\n\u003ctd\u003eNot expected before\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2036\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Patent Number Cited\u003c\/td\u003e\n\u003ctd\u003eU.S. Patent No.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10,696,730\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 GAAP Net Loss\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Investments (as of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$66.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eR\u0026amp;D Expenses for Q3 2025 were \u003cstrong\u003e$17.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash runway is expected to fund operations into \u003cstrong\u003eQ1 2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOther relevant patents include U.S. Patent No. \u003cstrong\u003e10,259,859\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eFinance: Q4 2025 Cash Burn Forecast\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company has not published a Q4 2025 cash burn forecast. Analyst consensus estimate for Q4 2025 loss was \u003cstrong\u003e$0.32 per share\u003c\/strong\u003e.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516110332053,"sku":"alxo-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/alxo-vrio-analysis.png?v=1740144782","url":"https:\/\/dcf-model.com\/pt\/products\/alxo-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}